Effect of Immunomodulatory Agents on Cortical Inflammatory Lesions in Patients with Relapsing-Remitting Multiple Sclerosis: A 2-Year Longitudinal Comparison Study.

Trial Profile

Effect of Immunomodulatory Agents on Cortical Inflammatory Lesions in Patients with Relapsing-Remitting Multiple Sclerosis: A 2-Year Longitudinal Comparison Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top